Author Interviews, Dermatology, Eli Lilly, Immunotherapy / 18.05.2023

MedicalResearch.com Interview with: Lotus Mallbris, MD PhD Dermatologist andSenior Vice President Global Immunology Development and Medical Affairs  Lilly   MedicalResearch.com: What is the background for this study?  Would you briefly describe what is meant by atopic dermatitis and types treated in this study? Response: First, this study specifically evaluated lebrikizumab, a novel, investigational, monoclonal antibody that selectively binds to interleukin 13 (IL-13) with high-affinity and high potency. Inflammation due to over-activation of the IL-13 pathway plays a central role in the pathogenesis of moderate-to-severe atopic dermatitis, commonly called eczema. This secondary analysis focused on patients treated with lebrikizumab from the 16-week induction periods of the ADvocate 1 and ADvocate 2 studies and the ADhere study. In the trials, we assessed the presence or absence of face or hand dermatitis in patients with moderate-to-severe atopic dermatitis. If present at baseline, at 16 weeks, clinicians assessed the change from baseline on a scale of cleared, improved, no change, or worsened. Only patients with face and hand dermatitis were evaluated as part of the analysis. (more…)
Author Interviews, Dermatology, JAMA / 15.05.2023

MedicalResearch.com Interview with: Matthew Zirwas, MD Founder, Bexley Dermatology Research Clinic Bexley, OH 43209 MedicalResearch.com: What is the background for this study? How does Roflumilast differ from other treatments for seb derm? Response: Seborrheic dermatitis affects up to 5% of the population globally and can have major impacts on quality of life. Treatment regimens are often complicated given the association of seborrheic dermatitis to hair bearing areas of the body, requiring multiple treatments for different parts of the body. Our phase 2 study aimed to understand the efficacy and safety of once-daily roflumilast foam 0.3% in adults with seborrheic dermatitis on their scalp, face and trunk. Roflumilast foam is a selective and highly potent phosphodiesterase (PDE) 4 inhibition that is being studied for a range of inflammatory skin conditions. (more…)
Author Interviews, Dermatology, Melanoma, USPSTF / 27.04.2023

MedicalResearch.com Interview with: John M. Ruiz, Ph.D Associate Professor of Clinical Psychology Department of Psychology University of Arizona Dr. Ruiz is the incoming editor-in-chief of the American Psychological Association (APA) journal, Health Psychology Dr. Ruiz joined the U.S. Preventive Services Task Force in January 2022     MedicalResearch.com: What is the background for this study? What are the main findings? Response: Skin cancer is the most common type of cancer in the United States, but it often does not cause serious complications or death. The Task Force’s recommendation on screening for skin cancer focuses on the effectiveness of visual skin exams for children and adults who do not have any symptoms. When reviewing the latest research, we found that there is currently not enough evidence to tell us whether or not screening people without signs or symptoms is beneficial. This is an I statement. (more…)
Author Interviews, Dermatology, Eli Lilly, NEJM / 26.03.2023

MedicalResearch.com Interview with: Jonathan Silverberg, MD, PHD, MPH Professor Director of Clinical Research Director of Patch Testing George Washington University School of Medicine and Health Sciences Washington, DC MedicalResearch.com: What is the background for this study? What are the main findings? Response: Lebrikizumab was previously shown to be safe and effective as a treatment for moderate-severe atopic dermatitis in a phase 2 study. These Phase 3 randomized placebo-controlled trials are the largest studies to date of lebrikizumab in AD. They showed that lebrikizumab was safe and highly effective for the treatment of moderate-severe atopic dermatitis. These studies will hopefully support the approval of lebrikizumab in the United States later this year. (more…)
Allergies, Author Interviews, Cancer Research, Dermatology, Melanoma / 17.03.2023

MedicalResearch.com Interview with: Jenni Komulainen University of Eastern Finland | UEF MedicalResearch.com: What is the background for this study? Response: The background for this study comes from the earlier findings that the skin cancer risk and atopic status have some connection, but the results have been inconsistent. The connection between atopy and skin cancers may be related to the stimulation of protective immune response or the predisposition to carcinogenesis through chronic inflammation. The aim of this study was to investigate if atopic disorders associate with skin cancers. (more…)
Allergies, Author Interviews, Dermatology / 09.03.2023

MedicalResearch.com Interview with: Nicholas Gulati, MD, PhD Director, Early Detection of Skin Cancer and Oncodermatology Clinic The Kimberly and Eric J. Waldman Department of Dermatology Mount Sinai Health System New York, New York MedicalResearch.com: What is the background for this study? What is dupilumab primarily used for? Response: Dupilumab is a monoclonal antibody that inhibits a specific part of the immune system known as Th2 cells, which are important in the development of various diseases including atopic dermatitis (eczema) and asthma. Therefore, dupilumab has become one of the major treatments for these conditions. Given the increasing use of this drug, it is important to understand the safety of it in terms of cancer development, as that is currently largely unknown. (more…)
Author Interviews, Cancer Research, Dermatology, Melanoma, Vitamin C / 10.01.2023

MedicalResearch.com Editors' note:  Please consult your health care provider before initiating any vitamin supplementation, including Vitamin D as potentially serious side effects are possible. MedicalResearch.com Interview with: Prof. Ilkka T Harvima Department of Dermatology University of Eastern Finland and Kuopio University Hospital Kuopio, Finland MedicalResearch.com: What is the background for this study? Response: The North Savo Skin Cancer Program in Eastern Finland was launched in 2017, and it aims at reducing the incidence, morbidity and mortality caused by skin cancers, such as basal cell carcinoma, squamous cell carcinoma and melanoma. A part of this program constituted a follow-up project of patients with an assessed risk of skin cancer. There are also several other parts, such as analysis of skin cancer material reposited in the Biobank of Eastern Finland (see the enclosed BMC Cancer 2021 reference), public information, education of general physicians and medical students etc. In 2021, we published the article in BMC Cancer (enclosed), where we attempted to clarify the reasons for the relatively high melanoma mortality in relation to its incidence in this region (North Savo) of the country. By using the biobank material we also published an article in 2022 showing that melanoma and melanoma in situ associate with keratinocytic premalignant lesions and keratinocyte skin carcinomas (Suhonen V, Siiskonen H, Suni M, Rummukainen J, Mannermaa A, Harvima IT. Malignant and in situ subtypes of melanoma are associated with basal and squamous cell carcinoma and its precancerous lesions. Eur J Dermatol 2022 Apr 1;32(2):187-194. doi: 10.1684/ejd.2022.4221.). The follow-up study of about 500 subjects is ongoing (COVID-19 caused pretty much trouble for the recruitment). This is focused on finding risk factors and biomarkers for skin cancers and carcinogenesis. The first study on these follow-up patients was published in 2021 (Komulainen J, Siiskonen H, Harvima IT. Association of elevated serum tryptase with cutaneous photodamage and skin cancers. Int Arch Allergy Immunol 2021;182(11):1135-1142. doi: 10.1159/000517287.). The article on vitamin D just recently published in Melanoma Research on Dec 28, 2022, is the second one. The third work in pipeline deals with the association of atopic disorders with skin cancers, and the manuscript is under revision. So, these provide with some background for the article in Melanoma Research. Actually, we thought that vitamin D use might associate with skin photoaging, actinic keratoses and carcinogenesis, but the only, though very important, finding was its association with melanoma. We have not focused our research just on vitamin D only, but it looks like we need to go further. (more…)
Author Interviews, Dermatology, Lancet / 13.12.2022

MedicalResearch.com Interview with: Dr. Emma Guttman-Yassky, MD, PhD Waldman Professor and System Chair The Kimberly and Eric J. Waldman Department of Dermatology Director, Center of Excellence in Eczema Director, Laboratory of Inflammatory Skin Diseases Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? What are the main findings? Response: The background for this study are studies that show that OX40 is a pathway that is upregulated in patients with atopic dermatitis (or eczema). OX40 is involved in activation of immune molecules associated with allergy and atopy, and also with formation of memory immune cells that are required for disease recurrence. The hypothesis to the study was that giving an OX40 antagonist will not only ameliorate the disease but perhaps have a remittive effect in that the disease will not come back. Indeed all drug doses were significantly effective at week 16, the primary endpoint compared to placebo and continued to improve towards week 36, the secondary endpoint. In addition, the responders to treatment maintained their responses for an additional 20 weeks, which is unusual, suggesting a potential for disease modification. (more…)
Aging, Author Interviews, Brigham & Women's - Harvard, Dermatology, Heart Disease, Herpes Viruses, Stroke / 23.11.2022

MedicalResearch.com Interview with:| Sharon G. Curhan, MD, ScM| Director, CHEARS: The Conservation of Hearing Study Channing Division of Network Medicine Department of Medicine Brigham and Women’s Hospital Harvard Medical School Boston, MA 02114 MedicalResearch.com: What is the background for this study? Response:       Herpes zoster, commonly known as “shingles,” is a viral infection that often causes a painful rash. Shingles can occur anywhere on the head or body. Shingles is caused by the varicella zoster virus (VZV), the same virus that causes chickenpox. After a person has chickenpox, the virus stays in their body for the rest of their life. Years and even decades later, the virus may reactivate as shingles. Almost all individuals age 50 years and older in the US have been infected with the varicella zoster virus and therefore they are at risk for shingles. About 1 in 3 people will develop shingles during their lifetime, and since age is a risk factor for shingles, this number may increase as the population ages. The risk is also higher among individuals of any age who are immunocompromised due to disease or treatment. A number of serious complications can occur when a person develops shingles, such as post-herpetic neuralgia (long-lasting pain), but there was limited information on whether there are other adverse long-term health implications of developing shingles. There is a growing body of evidence that links VZV, the virus that causes shingles, to vascular disease. VZV vasculopathy may cause damage to blood vessels and increase the risk of stroke or coronary heart disease. Although some previous studies showed a higher risk of stroke or heart attack around the time of the shingles infection, it was not known whether this higher risk persisted in the long term. Therefore, the question we aimed to address in this study was to investigate whether shingles is associated with higher long-term risk of stroke or coronary heart disease. To address this question, we conducted a prospective longitudinal study in 3 large US cohorts of >200,000 women and men, the Nurses’ Health Study (>79,000 women), the Nurses’ Health Study II (almost 94,000 women) and the Health Professionals Follow-Up Study (>31,000 men), without a prior history of stroke or coronary heart disease. We collected information on shingles, stroke and coronary heart disease on biennial questionnaires and confirmed the diagnoses with medical record review. We followed the participants for up to 16 years and evaluated whether those who had developed shingles were at higher risk for stroke or coronary heart disease years after the shingles episode. The outcomes we measured were incident stroke, incident coronary heart disease [defined as having a non-fatal or fatal myocardial infarction (heart attack) or a coronary revascularization procedure (CABG, coronary artery bypass graft or percutaneous transluminal coronary angioplasty)]. We also evaluated a combined outcome of cardiovascular disease, which included either stroke or coronary heart disease, whichever came first. (more…)
Author Interviews, Dermatology / 22.11.2022

MedicalResearch.com Interview with: Carlota Batres, Ph.D.Assistant Professor, Department of PsychologyDirector, Preferences Lab PreferencesLab.comFranklin and Marshall College MedicalResearch.com: What is the background for this study? Response: Previous research has found that complexion-oriented makeup products, such as foundation and concealer, make the skin appear more even. Interestingly, though, the effect size of perceptual judgements has been found to be larger than the effect size of physical measurements, suggesting that there are factors affecting the perception of skin evenness that are not captured by the physical measurements of isolated skin patches. (more…)
Dermatology, Lifestyle & Health / 28.10.2022

A recent scientific study found that Botox injections can help reduce the symptoms of mental health conditions like anxiety and depression, according to a report on Euronews. As more people seek non-invasive treatments to achieve beautiful, youthful, and natural looks, market experts predict that the medical spa industry will continue to grow. Currently, medspa therapies range from loose RNA that stimulates regeneration of skin to hydrafacials, microneedling, body sculpting, and laser hair removal. And while many people are embracing these medspa treatments, there are major concerns about their effectiveness. Keep reading to learn the science-backed health benefits of medical spa treatments. (more…)
Author Interviews, Cancer Research, Dermatology, Race/Ethnic Diversity / 18.10.2022

MedicalResearch.com Interview with: Alexandra J. White, PhD, MSPH Stadtman Investigator Epidemiology Branch National Institute of Environmental Health Sciences National Institutes of Health Research Triangle Park, NC MedicalResearch.com: What is the background for this study? What is the chemical primarily used in hair straighteners? Response: Hair products such as dye and chemical straighteners contain several different chemicals that may act as carcinogens or endocrine disruptors and thus may be important for cancer risk. Straighteners in particular have been found to include chemicals such as phthalates, parabens, cyclosiloxanes and metals and may release formaldehyde when heated. Previous research has suggested that hair dye and chemical straighteners are related to other hormone-sensitive cancers such as breast and ovarian cancer, but no previous study has considered how they are related to uterine cancer risk. (more…)
Author Interviews, Dermatology, Immunotherapy, NEJM, University of Pittsburgh / 06.10.2022

MedicalResearch.com Interview with: Rohit Aggarwal, MD, MS Rheumatology, Professor of Medicine Medical Director, Arthritis and Autoimmunity Center Sub-Specialty Education Coordinator Division of Rheumatology Department of Medicine University of Pittsburgh MedicalResearch.com: What is the background for this study? Response: Dermatomyositis is a rare autoimmune inflammatory disease that affects muscles and skin, although muscular forms without skin symptoms and vice versa are also seen. The exact etiology of the disease is not known but is thought to be immune-mediated with many patients having highly specific autoantibodies. There is no cure for dermatomyositis, but several types of treatment have been successfully used in the last years including different kinds of immunosuppressants (e.g. steroids) and intravenous immune globulins (IVIG) to improve the patient’s condition. So far, none of these treatments was approved for use in dermatomyositis based on large, randomized, placebo-controlled trials. Their effectiveness was mainly deduced from clinical experience and from small clinical trials. The ProDERM study was the first large, pivotal, randomized placebo-controlled trial to evaluate the efficacy and safety of intravenous immune globulin (IVIG) in dermatomyositis patients. (more…)
Author Interviews, Cancer Research, Dermatology, Melanoma / 22.09.2022

MedicalResearch.com Interview with: “Prof. Ronit Satchi-Fainaro, the Director of the Cancer Biology Research Center led this study with an outstanding PhD student, Sabina Pozzi” Prof. Ronit Satchi-Fainaro, Ph.D. Head, Cancer Research and Nanomedicine Laboratory Kurt and Herman Lion Chair in Nanosciences and Nanotechnologies Director, Cancer Biology Research Center Department of Physiology and Pharmacology Sackler Faculty of Medicine Sagol School of Neuroscience Tel Aviv University, Tel Aviv 69978, Israel MedicalResearch.com: What is the background for this study? Response: Cutaneous melanoma is the deadliest of all skin cancers, especially due to its tendency to invade and develop metastases with an incidence of brain metastasis development of 40% to 50% in patients with melanoma stage IV (although the incidence post mortem is 70–90%). We know that the brain microenvironment represents the first line of reaction in favor or against the tumor due to its dual ability to generate an immune-stimulatory or immunosuppressive niche, which will ultimately determine the establishment and growth of melanoma brain metastasis. Among the brain-resident cells, astrocytes are responsible for the maintenance of the brain homeostasis, and subsequent to melanoma brain colonization, they sustain and foster the growth of melanoma cells (more…)
Author Interviews, Cost of Health Care, Dermatology, JAMA / 08.09.2022

MedicalResearch.com Interview with: Jane M. Zhu, M.D., M.P.P., M.S.H.P. Assistant Professor of Medicine Division of General Internal Medicine and Geriatrics School of Medicine Oregon Health & Science University Portland, Oregon MedicalResearch.com: What is the background for this study? Response: Private equity (PE) acquisitions of physician practices are accelerating across many specialties, but there is still little robust evidence on the effects of these acquisitions. Concerns about PE involvement is predicated on the fact that these firms expect high annual returns, which require either reducing costs or increasing revenue, or both. Using PE acquisition data from 2016-2020, linked to commercial claims data, we sought to understand what common mechanisms of revenue generation were being adopted after private equity acquisition of physician practices. (more…)
Author Interviews, Dermatology, Infections / 15.07.2022

MedicalResearch.com Interview with: Dr Dilip Kachhawa, MD Department of Skin & Venereal Disease Dr Sampurnanand Medical College Jodhpur, Rajasthan, India MedicalResearch.com:  What are the main findings? Response: Molluscum Contagiosum (MC) is an infection caused by molluscipoxvirus. It is difficult to study since the virus only survives in human skin, and therefore there isn’t an animal or cell model to study potential treatments. Molluscum lesions appear as raised, domed shaped skin-colored lesions and can occur anywhere on the body but are most common on the face, neck, arms, legs, and abdomen. Sometimes there are few lesions, but clusters of several lesions can appear. Children are the most likely to get molluscum, and the virus is highly contagious, transmitted by direct contact with infected skin or contaminated objects, like towels, linens and toys. Scratching can cause autoinoculation which is when a person reinfects themself. MC is very common, impacting an estimated 6 million adults and mostly children in the US each year. In 2010, there was an estimated 122 million cases worldwide. It occurs primarily in humid and warm climates, and transmission via swimming pools and bathtubs may be possible. Therefore, molluscum is often called “water warts.” Many physicians may take a “watch and wait” approach since the virus may clear on its own. However, it can take months to up to 5 years for some to experience complete clearance, In the meantime, the person is still highly contagious and may spread the virus to others, particularly children. Lesions can be bothersome, causing itching and sometimes a secondary infection. There is also a psychosocial component. In a recent study, 1 in 10 children with molluscum experienced a major quality of life issue. Berdazimer Gel, 10.3% is a potential first-in-class topical controlled-nitric oxide releasing medication containing Berdazimer (sodium), a new chemical entity, and the active ingredient in berdazimer gel 10.3%. The mechanism of action of berdazimer in the treatment of molluscum is unknown, but in vitro lab studies show that the nitric oxide, released when berdazimer is combined with a hydrogel, may impede viral replication and perhaps help body’s natural immune response against molluscum. (more…)
Author Interviews, Dermatology / 14.05.2022

MedicalResearch.com Interview with: Naeem Bhojani, MD, FRCSC Division of Urology, Centre Hospitalier de l’Université de Montréal (CHUM), University of Montréal, Montréal, Québec, Canada David-Dan Nguyen MPH Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women’s Hospital, Harvard Medical School, Boston, MassachusettsFaculty of Medicine and Health Sciences, McGill University, Montréal, Québec, Canada  MedicalResearch.com:  What is the background for this study?  Response: In a recent study by our group published in JAMA Dermatology (https://jamanetwork.com/journals/jamadermatology/fullarticle/2772818), finasteride use was found to be associated with increased reporting of suicidality and depression in young patients with androgenetic alopecia. This previous analysis suggested that the association between finasteride and depression might be mediated by sexual dysfunction. Building on this work, we conducted this second analysis to examine the association between finasteride use and reports of sexual dysfunction. (more…)
Author Interviews, Dermatology, Race/Ethnic Diversity / 28.04.2022

MedicalResearch.com Interview with: Dr. Neelam Vashi MD Director of the Boston University Center for Ethnic Skin Dermatologist at Boston Medical Center, and Dr. Henriette De La Garza MD Research fellow Boston University School of Medicine   MedicalResearch.com:  What is the background for this study?  Response: The COVID-19 pandemic abruptly shifted many of our daily activities to an online world, dramatically increasing the use of electronic devices. Although visible light exposure from screens is small compared with the amount of exposure from the sun, there is concern about the long-term effects of excessive screen time. Recent studies have demonstrated that exposure to light emitted from electronic devices, even for as little as 1 hour, may cause reactive oxygen species generation, apoptosis, collagen degradation, and necrosis of skin cells. Visible light increases tyrosinase activity and induces immediate erythema in light-skinned individuals and long-lasting pigmentation in dark-skinned individuals. In recent years, tinted sunscreens have been rising in popularity because they are an effective and convenient way to protect against high-energy visible light while providing cosmetic benefits. The purpose of this analysis was to study current available options and product factors that may influence consumer preference when choosing a tinted sunscreen so dermatologists can improve their familiarity with available products and tailor their recommendations to patients with all skin tones. (more…)
Author Interviews, Dermatology, JAMA, Melanoma, University of Pittsburgh / 08.04.2022

MedicalResearch.com Interview with: Laura Ferris, M.D., Ph.D. Professor of Dermatology Director of clinical trials for UPMC Department of Dermatology University of Pittsburgh School of Medicine MedicalResearch.com:  What is the background for this study?  Response: In this quality initiative at UPMC (a large academic and community health system in Western PA and surrounding areas) Primary Care Physicians were trained to perform annual skin cancer screening examinations of their patients who were aged 35 years and older at routine medical visits. Over a 5-year period more than 595,000 patients who were eligible to be screened were seen by a UPMC PCP and about 24% of them were screened. We compared the number and thickness (an important indicator of prognosis) of the melanomas diagnosed in those patients who were screened to those who were not screened. (more…)
Author Interviews, Dermatology, Yale / 08.04.2022

MedicalResearch.com Interview with: Brett King, MD, PhD, FAAD Associate Professor of Dermatology Yale School of Medicine MedicalResearch.com:  What is the background for this study?  Response: Alopecia areata is an autoimmune disorder marked by disfiguring, non-scarring hair loss, and there are no therapies approved by the U.S. Food and Drug Administration for treatment of the disease. JAK inhibitors are showing promise for treatment of severe alopecia areata. In this work, the pooled results of two phase 3 clinical trials of the JAK inhibitor baricitinib were reported out to 52 weeks. (more…)
Abuse and Neglect, Author Interviews, Dermatology, JAMA, Pediatrics / 27.03.2022

MedicalResearch.com Interview with: Aaron Drucker MD, ScM, FRCPC Division of Dermatology, Department of Medicine, Women’s College Hospital Scientist, Women’s College Research Institute Assistant Professor, Department of Medicin and Institute of Health Policy, Management and Evaluation University of Toronto Adjunct Scientist, ICES  MedicalResearch.com:  What is the background for this study?  What are the main findings?   Response: Because atopic dermatitis is a chronic condition that is common in children, parents and physicians often wonder if it will affect overall child well-being, including their growth parameters. Previous studies were mostly cross-sectional, so we conducted a longitudinal study to follow children over time. We found that although young children with atopic dermatitis were somewhat shorter with higher BMI than children without atopic dermatitis, these differences were small and attenuated as children grew older. (more…)
Author Interviews, Dermatology, Diabetes / 22.02.2022

MedicalResearch.com Interview with: Chih-Shan Jason Chen, MD, PhD Director, Dermatologic and Mohs Micrographic Surgery Unit Memorial Sloan Kettering Skin Cancer Center at Hauppauge Attending Mohs Surgeon, Dermatology Service Memorial Sloan Kettering Cancer Center Chief, Dermatologic Surgery Northport VA Medical Center Associate Professor of Clinical Dermatology Renaissance School of Medicine at Stony Brook University MedicalResearch.com:  What is the background for this study?    Response: Managing a surgical wound on the lower leg can be a challenge. Often, higher wound tension, atrophic skin, edema, and compromised circulation result in higher risks of wound dehiscence and infection, and significantly limit the capacity of wound closure post-surgically. Therefore, healing by secondary intention is a practical option for many lower leg Mohs defects. However, a secondary intention wound on the lower leg is expected to take a longer time to heal. Certain factors such as older age and health conditions of the host may adversely affect healing time. Timolol is a nonselective beta-adrenergic receptor antagonist that has FDA approval for the treatment of glaucoma. In addition to this FDA-approved indication, topical timolol has several off-label uses in dermatology, such as for the treatment of infantile hemangiomas, venous stasis ulcers, and refractory wounds. Although timolol solution has been used in chronic wounds, knowledges of the efficacy and utility of timolol in an acute post-surgical wound setting is lacking. (more…)
Author Interviews, Dermatology, Emory, JAMA, Race/Ethnic Diversity / 27.01.2022

MedicalResearch.com Interview with: Howa Yeung, MD MScHe/him/his Assistant Professor of Dermatology Emory University School of Medicine Atlanta, GA 30322 MedicalResearch.com:  What is the background for this study?  Response: Asian Americans are the fastest growing racial group in the United States but are underrepresented in health research. Existing research often categorize Asian Americans into a single racial category, which may mask differences in health behaviors and outcomes subgroups. We sought to examine potential differences in skin cancer-related risk factors and screening among Asian Americans in a large, nationally representative study. (more…)
Allergies, Author Interviews, COVID -19 Coronavirus, Dermatology, UCSF / 27.11.2021

MedicalResearch.com Interview with: Carina M. Woodruff, MD Department of Dermatolog University of California, San Francisco MedicalResearch.com: What is the background for this study? What are the main findings? Response: Rigorous hand hygiene has been an important component of the CDC's COVID-19 guidelines. With millions of Americans now using hand sanitizers regularly, we are seeing many more cases of hand dermatitis. Our study evaluated the key product features and most common allergens in the top-reviewed, commercial hand sanitizers sold by major US retailers. We found that the most common potential allergens were tocopherol, fragrance, propylene glycol and phenoxyethanol. Our study also showed that nearly 1 in 5 marketing claims on these products was misleading. For example, 70% of sanitizers with the marketing claim "hypoallergenic" included at least one common allergen in its formulation. (more…)
Author Interviews, Cancer Research, Dermatology, Lancet, Melanoma, Technology / 11.11.2021

MedicalResearch.com Interview with: Dr David Wen BM BCh NIHR Academic Clinical Fellow in Dermatology University of Oxford MedicalResearch.com: What is the background for this study? Response: Publicly available skin image datasets are commonly used to develop machine learning (ML) algorithms for skin cancer diagnosis. These datasets are often utilised as they circumvent many of the barriers associated with large scale skin lesion image acquisition. Furthermore, publicly available datasets can be used as a benchmark for direct comparison of algorithm performance. Dataset and image metadata provide information about the disease and population upon which the algorithm was trained or validated on. This is important to know because machine learning algorithms heavily depend on the data used to train them; algorithms used for skin lesion classification frequently underperform when tested on independent datasets to which they were trained on. Detailing dataset composition is essential for extrapolating assumptions of generalisability of algorithm performance to other populations. At the time this review was conducted, the total number of publicly available datasets globally and their respective content had not previously been characterised. Therefore, we aimed to identify publicly available skin image datasets used to develop ML algorithms for skin cancer diagnosis, to categorise their data access requirements, and to systematically evaluate their characteristics including associated metadata.   (more…)
Author Interviews, COVID -19 Coronavirus, Dermatology, Respiratory / 06.10.2021

MedicalResearch.com Interview with: Lara van der Schoot  MD, PhD candidate Department of Dermatology Radboud University Medical Center Nijmegen, The Netherlands MedicalResearch.com: What is the background for this study? Response: Psoriasis is a chronic, immune mediated skin disease for which effective targeted biological agents have become available the past years. Inherent to their immunomodulatory mechanism of action, biologics might increase infections risk. We know from clinical trial data that respiratory tract infections are among the most common adverse events during biologic treatment, but real-world data is sparse. Regarding the risk of serious infections among biologic users, mostly defined as infections requiring hospitalization, previous studies provided different results and there is limited comparative data for the newer biologics available. The COVID-19 pandemic turned attention to the risk of infections among biologic users, especially for respiratory tract infections, as they might relate to susceptibility for viral respiratory tract infections such as COVID-19. In our study, the primary aim was to determine the risk of respiratory tract infections among real-world psoriasis patients treated with biologics, including the newer IL-17 and IL-23 inhibitors. The secondary aim was to assess risk of serious infections in this cohort. Additionally, rates of SARS-CoV-2 infections were assessed. (more…)
Author Interviews, Dermatology / 15.09.2021

MedicalResearch.com Interview with: Elena Ezhkova, PhD Professor, Department of Cell, Developmental, and Regenerative Biology Professsor, Dermatology Lab Head,The Black Family Stem Cell Institute Icahn School of Medicine at Mount Sinai New York Meng-Yen Li, PhD Postdoctoral Fellow The Black Family Stem Cell Institute MedicalResearch.com: What is the background for this study? Response: The epidermis is the primary barrier and the first line of defense to combat environmental stressors. The sun's ultraviolet (UV) is one of the main environmental stressors that our body is exposed to daily. UV produces DNA damage in epidermal cells and is a leading cause of skin cancers. To protect from the damaging effects of UV, epidermal cells become pigmented by melanocytes, pigment-producing cells. Taken up by epidermal cells, the melanin pigment absorbs UV light and reduces DNA damage. How the epidermis senses UV and how it leads to epidermal pigmentation is poorly understood. (more…)